|Bid||112.8500 x 100|
|Ask||113.0200 x 100|
|Day's Range||108.1250 - 117.4399|
|52 Week Range||31.3800 - 117.4399|
|PE Ratio (TTM)||-22.17|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alnylam could enter a new chapter in 2018 as it transitions into a commercial-stage company, an analyst said Thursday.
Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.